N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis
Duailibi MS, Cordeiro Q, Brietzke E, Ribeiro M, LaRowe S, Berk M, Trevizol AP
Published in The American Journal on Addictions
Methodology
Systematic review and meta-analysis of randomised placebo-controlled trials of N-acetylcysteine for craving across substance use disorders.
Key Findings
N-acetylcysteine significantly reduced craving symptoms compared with placebo across substance use disorders, with a favourable tolerability profile.
Conclusions
N-acetylcysteine reduces craving in substance use disorders.
Limitations
Small number of heterogeneous trials with differing substances, doses and craving scales.
Supplements Studied
N-acetylcysteine significantly reduced craving symptoms compared with placebo across substance use disorders.
Outcomes Measured
N-acetylcysteine significantly reduced craving symptoms compared with placebo.
Study Details
Access Study
Disclosures
Funding
Academic funding
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.